ArticleP & T : a peer-reviewed journal for formulary management2015
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.
Article in P & T : a peer-reviewed journal for formulary management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Sodium glucose co-transporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis in the emergency peri-operative period: a systematic review.Journal of anesthesia · 2025Pooled it
- Pooled it
- Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.Diabetes, obesity & metabolism · 2020Trial
- Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.Clinical and translational science · 2026Article
- Canagliflozin synergises with serine restriction mediating anti-leukaemic effects in T-cell acute lymphoblastic leukaemia.Molecular metabolism · 2025Article
- Pregnancy in Women Receiving Maintenance Dialysis.Kidney medicine · 2025Review
- Heme oxygenase, biliverdin reductase, and bilirubin pathways regulate oxidative stress and insulin resistance: a focus on diabetes and therapeutics.Clinical science (London, England : 1979) · 2025Review
- [Life-threatening euglycemic ketoacidosis under treatment with empagliflozin in cardiac surgery patients: rare isolated case or a frequent problem in the future?]Die Anaesthesiologie · 2024Article
- Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy.Cardiology and therapy · 2024Review
- Multivariate generalized mixed-effects models for screening multiple adverse drug reactions in spontaneous reporting systems.Frontiers in pharmacology · 2024Article
- Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.World journal of diabetes · 2023Article
- Dapagliflozin induces apoptosis by downregulating cFILPOncology letters · 2022Article
- SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.Heart failure reviews · 2022Review
- Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.Frontiers in cardiovascular medicine · 2022Review
- Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.International journal of molecular sciences · 2021 · on this mapArticle
- SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.Journal of clinical medicine · 2021Review
- A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Enhancing the Poor Flow and Tableting Problems of High Drug-Loading Formulation of Canagliflozin Using Continuous Green Granulation Process and Design-of-Experiment Approach.Pharmaceuticals (Basel, Switzerland) · 2020Article
- A comparison of the risk of cesarean section in gestational diabetes mellitus patients supplemented antenatally with vitamin D containing supplements versus placebo: A systematic review and meta-analysis of double-blinded randomized controlled trialsJournal of the Turkish German Gynecological Association · 2020Article
- Sodium-Glucose Cotransporter 2 Inhibitor-Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review.Clinical diabetes : a publication of the American Diabetes Association · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.
Indexed as
Identifiers
26185406PMC4495872W1415500254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.